177Lu-PSMA radioligand therapy demonstrates efficacy and safety in real-world metastatic castration-resistant prostate cancer

Prostate cancer is the second leading cause of cancer-related mortality in men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced stage where the disease progresses despite androgen deprivation therapy, posing significant treatment challenges. Traditional therapies often have limited efficacy or considerable side effects, highlighting an urgent need for novel, targeted interventions. Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using [177Lu]Lu-PSMA has emerged as a promising theranostic strategy, offering targeted radiation delivery to PSMA-expressing tumor cells.

This study retrospectively evaluated the efficacy and safety of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The research was conducted in a hospital clinical setting, reflecting real-world treatment experiences. Patients received standard clinical doses of 177Lu-PSMA as part of their treatment regimen. Primary endpoints included assessment of treatment efficacy and safety profiles. Specific patient numbers, dosing protocols, and follow-up durations were not detailed in the abstract.